M. Sáez

Radium-223 international early access program: results from the Spanish subset.

J. Carles, B. Mellado, E. Esteban, 2018, Future oncology.

A phase Ib open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with abiraterone or enzalutamide in metastatic castrate-resistant prostate cancer.

J. Carles, B. Mellado, J. Bono, 2018 .

Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study

I. Chirivella, E. Gallardo, B. Mellado, 2016, BMC Cancer.

Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study

I. Chirivella, E. Gallardo, B. Mellado, 2016, BMC Cancer.

Early responses to enzalutamide in AR-V7 positive first line metastatic castration-resistant prostate cancer (mCRPC). A prospective SOGUG clinical trial: The PREMIERE study

M. Climent, E. Gallardo, B. Mellado, 2016 .

Randomized phase II study of docetaxel (D) + abiraterone acetate (AA) versus D after disease progression to first-line AA in metastatic castration-resistant prostate cancer (mCRPC): ABIDO-SOGUG Trial.

B. Mellado, E. Esteban, A. Font, 2020 .

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study

D. Amadori, D. Dearnaley, M. Climent, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of CTC detection by AdnaTest with outcome on enzalutamide in chemotherapy-naïve castration-resistant prostate cancer: Exploratory results from PREMIERE—A SOGUG trial.

E. Gallardo, B. Mellado, D. Castellano, 2017 .